Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Meram
Melun, France
- Ownership
- Private
- Employees
- ~185
- Development stage
- Other
01
Overview
Laboratoires Meram, commonly known as Meram, was a French pharmaceutical company specialized in hospital-administered therapies and specialty medicines. Established in 1923 and headquartered in Melun, France, the firm built a robust portfolio centered on infectiology, cardiovascular health, and emergency medicine. Meram was particularly recognized for its range of injectable antibiotics and critical care treatments utilized across European healthcare systems. In 2008, the company was acquired by Mylan for approximately $197 million to strengthen Mylan's presence in the specialty and hospital sectors. Today, its legacy products and operations are integrated into Viatris following the merger of Mylan and Upjohn.
- Therapeutic areas
- CardiovascularInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Meram.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meram.